Wondering how a short strand of genetic code becomes a usable platform? mRNA technology explained simply: a synthetic message tells your cells to make one protein, then it is broken down.
This guide is part of our wider series on what is biotechnology.
| Item | Value |
|---|---|
| Structural sections of in vitro-transcribed mRNA | Five: 5′ cap, 5′ UTR, open reading frame, 3′ UTR, poly(A) tail |
| Poly(A) tail length described as necessary | 100-150 bp |
| Cold-chain range cited for mRNA vaccines | -20 °C to -80 °C |
| Main delivery vehicle emphasised in the review | Lipid nanoparticles |
Figures come from a Nature Reviews Drug Discovery review and a PubMed Central review. Details can change as the field moves, so check the sources before you rely on them.
mRNA technology explained: what it is and why it is a platform
Messenger RNA is the molecule cells use to carry a protein recipe to the ribosome, where the protein is built.
The Nature review describes how this design underlies mRNA vaccines for infectious diseases. This page explains the biology only and makes no claims about how well any specific product performs.
The anatomy of a synthetic mRNA molecule
According to the Nature Reviews Drug Discovery review, in vitro-transcribed (IVT) mRNA mimics the structure of natural mRNA, with five sections from 5′ to 3′. Each part has a job:
- 5′ cap: protects the molecule from exonucleases and helps recruit ribosomes.
- 5′ and 3′ untranslated regions (UTRs): engineered to limit degradation.
- Open reading frame: the sequence that encodes the protein of interest, such as a viral antigen.
- Poly(A) tail: a tail of 100-150 bp is described as necessary to interact with poly(A) binding proteins.
The same review notes that the sequence typically incorporates modified nucleosides, such as pseudouridine or N1-methylpseudouridine, to maximise translation.
How synthetic mRNA is made
Unlike older biologics grown in living cells, mRNA is made in a cell-free reaction. The Nature review says clinically used synthetic mRNA is transcribed in vitro from a DNA plasmid using the bacteriophage RNA polymerase T7, and that T3 and SP6 polymerases can also be used.
A simplified view of the pipeline looks like this:
- A DNA template encoding the protein is prepared. The poly(A) tail can be encoded in that template, which the review says reduces production time and material loss.
- The polymerase copies the template into mRNA, and a cap is added during transcription.
- The product is purified to remove double-stranded RNA (dsRNA) contaminants, reactants and incomplete transcripts.
- The purified mRNA is mixed with lipids so it is encapsulated in nanoparticles.
Because the template is only DNA and the reaction is cell-free, changing the target protein mainly means changing the template sequence. That is the practical meaning of a platform in this field, although each new sequence still has to be tested for how it behaves.
The review also describes a variation called self-amplifying mRNA, which contains replicase genes that encode an RNA-dependent RNA polymerase. It is a separate design with its own trade-offs, and this page does not compare them.
How the message gets into a cell
Bare mRNA is fragile. The review states that inside the body it is engulfed by cells of the innate immune system and degraded by nucleases, so it needs packaging.
The common answer is the lipid nanoparticle (LNP). The review says LNPs typically include four components, which together encapsulate and protect the fragile mRNA core:
- an ionizable lipid;
- cholesterol, which it says enhances stability by filling gaps between lipids;
- a helper phospholipid;
- a PEGylated lipid, made of polyethylene glycol conjugated to an anchoring lipid.
In the review’s manufacturing description, purified mRNA is mixed with lipids in a microfluidic mixer, and the lipids encapsulate the mRNA as self-assembled nanoparticles.
Once inside a cell’s endosome, the review says the lipids are positively charged in the acidic environment, which promotes fusion with the endosomal membrane and release into the cytoplasm. The mRNA is then read by ribosomes, and the cell makes the encoded protein.
Design choices that shape how a sequence behaves
Choosing the coding sequence is only part of the design work. The Nature review describes several levers that developers tune around it:
- UTR engineering: engineered UTR sequences minimise degradation by excluding miRNA-binding sites and AU-rich regions in the 3′ UTR.
- Scanning-friendly structure: designs minimise regions that prevent ribosomes from scanning the transcript, such as hairpins in the 5′ UTR.
- Nucleoside choice: modified nucleosides are typically incorporated to maximise translation.
- Purification: removing dsRNA contaminants and incomplete transcripts is part of the process.
Each lever interacts with the others. A change that raises protein output in one setting may alter stability or handling in another, which is why design is an iterative, experimental process.
The lipid side is tuned too. The review notes that several studies have shown improved efficacy with cholesterol analogues, which likely reduce binding to a trafficking protein. The word “likely” matters: the mechanism is a proposed explanation, not a closed question.
Where this fits with other omics tools
mRNA design sits alongside methods that measure what cells are doing. Readers curious about measuring RNA in individual cells can see single cell rna sequencing explained, while protein-level readouts are covered in proteomics explained.
Whatever the design method, a sequence or lipid formulation has to be made and tested in the laboratory before anyone knows how it behaves.
Limits and open problems
A PubMed Central review lists several limitations, including toxicity concerns, limited information about immune pathways, the need to maintain a cold chain, and the need to optimise administration methods.
The same review says mRNA is intrinsically unstable and vulnerable to enzymatic breakdown. It also states that mRNA vaccines require a cold chain of -20 °C to -80 °C, which is challenging for resource-constrained settings.
Delivery is also a bottleneck. As the Nature review reports, that a protein involved in trafficking cholesterol recycles about 70% of LNPs from late endosomes back out of the cell, so much of the dose may never reach the cytoplasm.
These limits are why published claims about any mRNA product deserve careful reading, and why a design that works on paper may behave differently in cells. Nothing here is medical advice: talk to a physician or other qualified clinician about any health decision, and note that this site does not rank or recommend any product.
The reviews also show how much is still being worked out. The PubMed Central review describes ongoing efforts with alternative carriers, and it says one carbon-nanotube platform, NanoVac, preserved mRNA from degradation and reduced efforts to maintain a cold chain. Whether such approaches hold up broadly is a question for further research, not a settled result.
Frequently asked questions
Is mRNA the same as DNA?
Show answer
No. mRNA is a transient copy of instructions used to build a protein. The Nature review describes it as degraded by nucleases, so it is not a permanent record.
Why are lipid nanoparticles used?
Show answer
Unprotected mRNA is degraded in the body. The Nature review describes LNPs as the main non-viral vehicle that encapsulates it and helps release it into the cytoplasm.
Why do some mRNA vaccines need freezing?
Show answer
The PubMed Central review says mRNA is intrinsically unstable and cites a cold chain of -20 °C to -80 °C. Research on alternative carriers aims to reduce that need.
What are modified nucleosides for?
Show answer
The Nature review says they are typically included to maximise translation.
This article is for information only. It is general education about science and the drug industry, and it is not medical, treatment or investment advice.
